Authorised Use

On February 24,2022 the LEPL Regulation Agency for Medical and Pharmaceutical Activities of the Ministry of Internally Displaced Persons from Occupied Territories, Labour, Health and Social Affairs of Georgia has granted Emergency Use Authorization of the unapproved product PAXLOVID for the treatment of COVID 19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID 19.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions to Pfizer via https://www.pfizersafetyreporting.com/.

The product information linked to the QR Code on the product pack has the latest updated product information approved in your country, which may be more up to date than the paper leaflet.

Read the PAXLOVID™ Summary of Product Characteristics